Why the new drug for Alzheimer's disease is causing controversy
Jun 24, 2021•25 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
The U.S. Food and Drug Administration gave "accelerated approval" this month to the first new drug to treat Alzheimer's disease in nearly two decades. But there is controversy over the efficacy of the drug, as well as its cost and side effects. Saska Sivananthan, chief of research and knowledge translation for the Alzheimer Society of Canada, breaks down what we know so far about the drug.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast